Strontium-89 for bone metastases from prostate cancer: an update / 中华男科学杂志
National Journal of Andrology
;
(12): 269-272, 2010.
Article
in Chinese
| WPRIM
| ID: wpr-252816
ABSTRACT
Strontium-89 (Sr-89) is a pure emitter with maximum beta energy of 1.46 MeV, average beta energy of 0.58 MeV, and a physical half-life of 50.5 days. It is rapidly taken up by bone and preferentially retained at the sites of osseous metastases. Its biological half-life is >50 days at the metastatic sites, but about 14 days only in the normal bone. The dose of its absorption in the tumor-bearing bone ranges from 21 +/- 4 to 231 +/- 56 cGy/MBq, 2-25 times higher than in the normal bone. Strontium-89 therapy is an effective palliative treatment of bone metastases from prostate cancer, with analgesic effectiveness in 80%.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Prostatic Neoplasms
/
Radiotherapy
/
Strontium Radioisotopes
/
Bone Neoplasms
/
Therapeutic Uses
/
Neoplasm Metastasis
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2010
Type:
Article
Similar
MEDLINE
...
LILACS
LIS